Filing Flows › Health Care › Jazz Pharmaceuticals (JAZZ)
Jazz Pharmaceuticals (JAZZ) earnings and revenue breakdown
Latest: Q3 2026 · 10-Q filed Nov 2, 2026 · Jazz Pharmaceuticals (JAZZ) Q3 2026 earnings results →
Q3 2026 Revenue up 10% year over year to $1.2B · 39¢ of every $1 of revenue lost · operating margin -33.3%
Jazz Pharmaceuticals made $1.2B in Q3 2026 (+10% Y/Y): Sleep $514M, Xywav $482M, Rylaze/Enrylaze $106M. Operating margin -33.3%, net loss $483M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Nov 2, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $1.2B in Q3 2026, up 10% year over year and up 3% from the previous quarter. Sleep was the largest line at 41% of revenue. Modeyso added $0.05B year over year (up 455%), 43% of the total change. High-sodium oxybate AG royalty revenue declined 27%.
Operating costs exceeded revenue by $0.41B, an operating margin of -33.3%. Total costs grew 55% against revenue growth of 10%. The fastest-growing cost line was Other operating costs (+205%). The quarter ended with a net loss of $0.48B, after a profit of $0.19B the previous quarter.
Operating cash flow was $0.51B (up 7% year over year). Non-cash charges added back $0.18B of depreciation and amortization and $0.08B of share-based compensation. Working capital and other items added $0.73B. Capital expenditures of $0.02B left free cash flow of $0.49B.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q3 2026 | 10-Q | Nov 2, 2026 | $1.2B | +10% | -33.3% | −$483M | $506M |
| Q2 2026 | 10-Q | Aug 3, 2026 | $1.2B | +16% | 20.5% | $193M | $416M |
| Q1 2026 | 10-Q | May 5, 2026 | $1.1B | +19% | 31.5% | $293M | $408M |
| Q4 2025 | 10-K | Feb 24, 2026 | $1.2B | +10% | 21.2% | $203M | $362M |
| Q3 2025 | 10-Q | Nov 5, 2025 | $1.1B | +7% | 5.1% | $251M | $475M |
| Q2 2025 | 10-Q | Aug 6, 2025 | $1.0B | +2% | -65.6% | −$718M | $88.8M |
| Q1 2025 | 10-Q | May 7, 2025 | $898M | -0.5% | -6.2% | −$92.5M | $430M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
Customers and suppliers named in filings
Sells to
About Jazz Pharmaceuticals
Jazz Pharmaceuticals plc is a global biopharmaceutical company whose purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing life-changing medicines for people with rare disease – often with limited or no therapeutic options. We have a diverse portfolio of medicines, including leading therapies addressing epilepsies, cancers and sleep disorders. Our patient-focused and science-driven approach powers pioneering R&D advancements across our robust pipeline of innovative therapeutics. • Xywav® (calcium, magnesium, potassium, and sodium oxybates) oral solution , a product approved by FDA in July 2020, and launched in the U.S. in November 2020 for the treatment of cataplexy or EDS in patients seven years of age and older with narcolepsy, and also approved by FDA in August 2021 for the treatment of IH in adults and launched in the U.S.
In its own words, from its 10-K, filed Feb 24, 2026.
Jazz Pharmaceuticals against its Pharmaceutical Preparations peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: +10% against the peers' median +10%. Operating margin: -33.3% against the peers' median 20.4%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| JAZZ Jazz Pharmaceuticals | Q3 2026 | $1.2B | +10% | -33.3% |
| JNJ Johnson & Johnson | Q3 2026 | $25.4B | +6% | 0.1% |
| LLY ELI Lilly | Q3 2026 | $24.4B | +39% | 34.5% |
| MRK Merck | Q3 2026 | $18.1B | +5% | 30.7% |
| ABBV AbbVie | Q3 2026 | $17.4B | +10% | 36.0% |
| PFE Pfizer | Q3 2026 | $16.6B | -0.4% | 20.4% |
| BMY Bristol Myers Squibb | Q3 2026 | $13.1B | +7% | 19.4% |
| ABT Abbott Laboratories | Q3 2026 | $13.0B | +14% | 10.4% |
| REGN Regeneron Pharmaceuticals | Q3 2026 | $5.1B | +36% | 40.0% |
Source: Jazz Pharmaceuticals 10-Q on SEC EDGAR · CIK 1232524 · Pharmaceutical Preparations
Guidance and outlook
More on JAZZ
- How Jazz Pharmaceuticals makes money: revenue by segment
- Jazz Pharmaceuticals next earnings date and what analysts expect
- Jazz Pharmaceuticals stock forecast, price target and fair value
- Jazz Pharmaceuticals guidance and outlook
- Is Jazz Pharmaceuticals a takeover target? LBO and rumors
- Jazz Pharmaceuticals recalls, complaints and regulation
History
Every quarter: Q3 2026 results · Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results
- Jazz Pharmaceuticals guidance history: guided vs reported
- Jazz Pharmaceuticals operating margin by quarter
- Jazz Pharmaceuticals net income by quarter
- Jazz Pharmaceuticals free cash flow by quarter
- Jazz Pharmaceuticals R&D spending by quarter
- Jazz Pharmaceuticals capital expenditures by quarter
- Jazz Pharmaceuticals Rylaze/Enrylaze revenue by quarter